Abstract:
A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.]
Abstract:
A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.
Abstract:
Salts of 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole and their crystalline and amorphous forms.
Abstract:
A free-space optical receiving apparatus in one embodiment of the invention is provided with: a signal receiving light-sensitive element that converts an infrared signal to an electric current signal; a current-voltage conversion circuit that converts the electric current signal to a voltage signal; a shared processing circuit that amplifies this voltage signal, performs digital conversion on the voltage signal, and outputs a digital signal; and a mode conversion circuit that switches the shared processing circuit to a remote control mode when an infrared signal is received, and switches the shared processing circuit to an IrSimple mode when an IrSimple signal is received. The shared processing circuit converts the remote control signal to a digital signal when in the remote control mode, and converts the IrSimple signal to a digital signal when in the IrSimple mode.
Abstract:
In an optical movement information detector, light emitted from a laser diode (1) is split into a first beam (10), a second beam (11) and a third beam (12) by beam splitters (2a, 2b). The first, second and third beams are converged by a condenser lens (4) upon a surface of an object to be measured (5) to form a beam spot (13) thereon. Diffused light from the beam spot (13) is received by a photodiode (6) and an output signal of the photodiode (6) is processed by a signal processing circuit (20) including an analog-digital converter (8) and a Fourier transforming unit (9). A detecting section (21) obtains, for example, a moving velocity and a moving direction of the object based on spectrum peak frequencies obtained by the Fourier transform.
Abstract:
Amidino derivatives represented by the following general formula (I): {where X is a group represented by R1SO2NR2— (wherein R1 represents optionally substituted C6-14 aryl, etc. and R2 represents hydrogen atom, etc.), etc., Ar1 represents 2,6-naphthylene, etc., R3 represents hydrogen atom, etc. and Y represents carboxyphenyl, etc.} and their pharmacologically acceptable salts or solvates.
Abstract:
In an optical movement information detector, light emitted from a laser diode (1) is split into a first beam (10), a second beam (11) and a third beam (12) by beam splitters (2a, 2b). The first, second and third beams are converged by a condenser lens (4) upon a surface of an object to be measured (5) to form a beam spot (13) thereon. Diffused light from the beam spot (13) is received by a photodiode (6) and an output signal of the photodiode (6) is processed by a signal processing circuit (20) including an analog-digital converter (8) and a Fourier transforming unit (9). A detecting section (21) obtains, for example, a moving velocity and a moving direction of the object based on spectrum peak frequencies obtained by the Fourier transform.
Abstract:
The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.
Abstract translation:本发明提供了一种基于腺苷A2受体拮抗剂作用的新型糖尿病和糖尿病并发症的预防或治疗剂。即提供了具有腺苷A2受体拮抗剂作用的新颖的缩合咪唑化合物,是 有效预防或治疗糖尿病和糖尿病并发症,并由式(I)表示;(其中R 1表示例如可被烷基取代的氨基; R 2表示例如氢原子, 可以被羟基取代的烷基,环烷基或烷基,烯基或炔基; R 3表示例如任选取代的烷基,烯基,炔基,芳基,杂芳基, 吡啶酮基,嘧啶酮基或哌嗪酮基; Ar表示例如任选取代的芳基或杂芳基; Q和W彼此相同或不同,每个代表 N或CH),其药理学上可接受的盐或其水合物。
Abstract:
Wafers are previously positioned so that the wafer orientation flat is oriented in a particular direction. A transporting means then moves and places the previously positioned wafer on a bonding stage where bumps are formed on the wafer by means of a bonding head. The transporting means has a sensor for detecting the position of the orientation flat of a wafer on the bonding stage from a position above the bonding stage, thereby avoiding the adverse effects of heat from the bonding stage during orientation flat detection.
Abstract:
The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## �in formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring; ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each a hydrogen atom, a halogen atom or a group such as a lower alkoxy group; R.sup.5 represents a group represented by the formula --NR.sup.11 R.sup.12 (wherein R.sup.11 and R.sup.12 represent each a hydrogen atom or a group such as a lower alkyl group) or the like; and R.sup.6 represents a group represented by the formula ##STR2## (wherein R.sup.19 represents a hydrogen atom, a lower alkyl group or the like; R.sup.20, R.sup.21 and R.sup.22 represent each a hydrogen atom, a halogen atom, a hydroxyl group or the like; and r represents 0 or an integer of 1 to 8)!.